DELRAY BEACH, Fla., March 14, 2017 -- PositiveID Corporation (“PositiveID” or “Company”) (OTC:PSID), a life sciences company focused on detection and diagnostics, announced today that its E-N-G Mobile Systems subsidiary (“ENG”) year-to-date bookings through February 28, 2017, total $1.7 million, which is an increase of more than 200 percent over total bookings in the prior sequential quarter.
Bookings represent signed purchase orders or contracts received from customers. The majority of the bookings are for ENG’s customized mobile lab vehicles. ENG’s MobiLab line is field-proven and available in a wide range of platforms including vans, truck-based systems and trailers up to 53 feet. Applications range from general purpose and chemistry labs to BSL3-ready and full CBRNE (chemical, biological, radiological, nuclear and explosives) threat detection and analysis.
“ENG’s pipeline is strong and we believe sets us up for another successful year,” stated Lyle L. Probst, President of PositiveID. “We have worked diligently to establish our mobile labs business amongst the best in the industry both domestically and internationally, and we believe the current pipeline for ENG’s mobile labs is evidence that hard work is paying off.”
ENG designs and builds mobile laboratories, wireless support vehicles (cell-on-wheels and cell-on-light-trucks), radio frequency (“RF”) test platforms, broadcast news vehicles, and other technical vehicles. ENG has delivered more than 1,400 specialty vehicles to customers around the globe, including more than 400 mobile laboratories, 600 broadcast news vehicles, and more than 400 vehicles for cellular, RF, infrared, and other applications.
About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations, including the likelihood that ENG’s pipeline is strong and it sets up the company for another successful year; the likelihood that the current pipeline for ENG’s mobile labs is evidence that ENG’s mobile labs business amongst the best in the industry both domestically and internationally; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the specialty vehicle market; the Company’s ability to attract new customers and retain existing customers; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on November 18, 2016, August 12, 2016, and May 16, 2016, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contacts: PositiveID Corporation Allison Tomek (561) 805-8044 [email protected] RedChip Companies Jon Cunningham (407) 644-4256 [email protected]


Bain Capital Moves to Acquire Majority Stake in Echo Marketing
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 



